[Skip to Content]
[Skip to Content Landing]
September 1949


Author Affiliations


From the Departments of Medicine and Pathology of the Bronx Hospital and the Office of the New York City Medical Examiner.

Arch NeurPsych. 1949;62(3):358-360. doi:10.1001/archneurpsyc.1949.02310150105011

THE WIDE use of trimethadione (3, 5, 5-trimethyloxazolidine-2, 4-dione, tridione,® Abbott) for the control of petit mal and of psychomotor seizures compels the careful evaluation of toxic effects of the drug and comparison of these effects with the results to be achieved by its use. In 1946 DeJong1 reported that no serious reactions to trimethadione had yet been observed and that the only untoward effects noted were nausea, drowsiness and lightheadedness. Later in the same year Harrison, Johnson and Ayer2 reported a case of fatal aplastic anemia following the simultaneous use of trimethadione and a hydantoin. Mackay and Gottstein3 reported a case of their own of fatal agranulocytosis and aplastic anemia attributable solely to trimethadione, and Greaves4 reported a case of agranulocytosis with recovery in a patient who had also been receiving the drug. In 1948, Carnicelli and Tedeschi5 added a fourth case of